AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound having a structure according to Formula (I):



(I)

wherein:

a. each R^1 is selected from the group consisting of lower alkyl, CN, and halo;

b. m is an integer 1 or 2;

c. Q is  ;

d. ~~each~~ R^2 is H;

e. R^3 is selected from the group consisting of: H, alkyl, OH, OR^4, and SR^4;

f. X is CH;

g. Y is N;

h. A is selected from the group consisting of: C(O) and N-G;

i. B is selected from the group consisting of: C(O) and N-G;

j. Provided that one and only one of A or B is C(O);

k. G is selected from the group consisting of: alkyl, cycloalkyl, aryl, heteroalkyl, heterocycloalkyl, heteroaryl, OR^4 and $S(O)_2R^4$;

l. each R^4 is independently selected from H, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, and heteroaryl;

m. each R^5 is independently selected from H, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, OR^4, and $S(O)_2R^4$;

or an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt thereof.

PAGE 3/7 * RCVD AT 1/25/2005 3:02:01 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/5 * DNIS:8729306 * CSID:513 622 3300 * DURATION (mm-ss):02-08

2. (Currently amended) The compound according to Claim 1 wherein ~~G is~~ G is selected from the group consisting of: alkyl, aryl, heteroalkyl, and heterocycloalkyl.

3. (Original) The compound according to Claim 1 wherein R^4 is selected from the group consisting of: phenyl, lower alkyl, and heteroaryl.

4. (Currently amended) The compound according to Claim 3 herein each R^1 is independently selected from the group consisting of: F, Cl, CF_3, CN, and CH_3.

5. (Original) The compound according to Claim 4 herein A is C(O).

6. (Original) The compound according to Claim 4 herein B is C(O).

7. (Original) A compound selected from the group consisting of:

4-(4-Fluorophenyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

2-Ethoxymethyl-4-(4-fluorophenyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-(4-methylpiperazine-1-carbonyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-(morpholine-4-carbonyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

2-Allyl-4-(4-fluorophenyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(2-hydroxyphenoxy)-pyrimidin-4-yl]-isoxazol-5-one;

2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(3-hydroxyphenoxy)-pyrimidin-4-yl]-isoxazol-5-one;

2-Ethoxymethyl-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-5-yl)-2*H*-isoxazol-5-one;

PAGE 4/7 * RCVD AT 1/25/2005 3:02:01 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/5 * DNIS:8729306 * CSID:513 622 3300 * DURATION (mm-ss):02-08

3-{2-[(2-cyano)-methylamino]-2-ethoxymethyl-4-(4-fluorophenyl)-pyrimidin-4-yl}-2*H*-isoxazol-5-one;

3-[2-(Benzylamino)-pyrimidin-4-yl]-2-ethoxymethyl-4-(4-fluorophenyl)-isoxazol-5-one;

(*R*)-2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-isoxazol-5-one;

(*S*)-2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-isoxazol-5-one;

N-(2-{4-[2-Ethoxymethyl-4-(4-fluorophenyl)-5-oxo-2,5-dihydro-isoxazol-3-yl]-pyrimidin-2-yloxy}-phenyl)-acetamide;

2-Ethoxymethyl-4-(4-fluorophenyl)-3-[2-(2-methylamino-phenoxy)-pyrimidin-4-yl]-2*H*-isoxazol-5-one;

2-Ethoxymethyl-4-(4-fluorophenyl)-3-{2-[(2-hydroxyphenyl)-methylamino]-pyrimidin-4-yl}-2*H*-isoxazol-5-one;

2-Allyl-4-(4-fluorophenyl)-3-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

2-Allyl-4-(4-fluorophenyl)-3-(2-phenoxypyrimidin-5-yl)-2*H*-isoxazol-5-one;

[4-(4-Fluorophenyl)-5-oxo-3-(2-phenoxypyrimidin-4-yl)-5*H*-isoxazol-2-yl]-acetaldehyde;

2-(*N,N*-Dimethylaminoethyl)-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

2-(*N,N*-Diethylaminoethyl)-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-(2-piperazin-1-ylethyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-(2-piperidin-1-ylethyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-(2-morpholin-4-ylethyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)2-(2-pyrrolidin-1-ylethyl)-2*H*-isoxazol-5-one;

PAGE 5/7 * RCVD AT 1/25/2005 3:02:01 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/5 * DNIS:8729306 * CSID:513 622 3300 * DURATION (mm-ss):02-08

2-[2-(2-Amino-ethylamino)ethyl]-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

4-(4-Fluorophenyl)-2-[2-(2-hydroxy-ethylamino)ethyl]-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

[2-(2-Dimethylamino-ethylamino)-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one;

(2-Ethylamino-ethyl)-4-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-2*H*-isoxazol-5-one; and

3-(4-Fluorophenyl)-4-(2-methylsulfanyl-pyrimidin-4-yl)-2*H*-isoxazol-5-one.

8. (Original) A pharmaceutical composition comprising:

(a) a safe and effective amount of a compound of Claim 1 ~~Claim 21~~; and

(b) a pharmaceutically-acceptable carrier.

9. (Original) A method for treating osteoarthritis, the method comprising administering to said subject a safe and effective amount of a compound of Claim 1.

10. (Original) A method for treating rheumatoid arthritis, the method comprising administering to said subject a safe and effective amount of a compound of Claim 1.

11. (Original) A method for treating congestive heart failure, the method comprising administering to said subject a safe and effective amount of a compound of Claim 1.

PAGE 6/7 * RCVD AT 1/25/2005 3:02:01 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/5 * DNIS:8729306 * CSID:513 622 3300 * DURATION (mm-ss):02-08